Deborah Ayeni
Overview
Explore the profile of Deborah Ayeni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna R, Traina K, Robles-Oteiza C, et al.
Cancer Discov
. 2024 Jan;
:OF1-OF22.
PMID: 38270272
Significance: Alternate strategies harnessing anticancer innate immunity are required for lung cancers with poor response rates to T cell-based immunotherapies. This study identifies a targetable, mutually supportive, metabolic relationship between...
2.
Kuhlmann-Hogan A, Cordes T, Xu Z, Kuna R, Traina K, Robles-Oteiza C, et al.
Cancer Discov
. 2024 Jan;
PMID: 38241033
The limited efficacy of currently approved immunotherapies in EGFR-driven lung adenocarcinoma (LUAD) underscores the need to better understand alternative mechanisms governing local immunosuppression to fuel novel therapies. Elevated surfactant and...
3.
Kuhlmann-Hogan A, Cordes T, Xu Z, Traina K, Robles-Oteiza C, Ayeni D, et al.
bioRxiv
. 2023 May;
PMID: 37131637
The limited efficacy of currently approved immunotherapies in EGFR-mutant lung adenocarcinoma (LUAD) underscores the need to better understand mechanisms governing local immunosuppression. Elevated surfactant and GM-CSF secretion from the transformed...
4.
Robles-Oteiza C, Ayeni D, Levy S, Homer R, Kaech S, Politi K
Dis Model Mech
. 2021 Sep;
14(11).
PMID: 34494649
Conditional ablation of defined cell populations in vivo can be achieved using genetically engineered mice in which the human diphtheria toxin (DT) receptor (DTR) is placed under control of a...
5.
Foggetti G, Li C, Cai H, Hellyer J, Lin W, Ayeni D, et al.
Cancer Discov
. 2021 Mar;
11(7):1736-1753.
PMID: 33707235
In lung adenocarcinoma, oncogenic mutations co-occur with many tumor suppressor gene alterations; however, the extent to which these contribute to tumor growth and response to therapy remains largely unknown. By...
6.
Starrett J, Guernet A, Cuomo M, Poels K, van Alderwerelt van Rosenburgh I, Nagelberg A, et al.
Cancer Res
. 2020 Mar;
80(10):2017-2030.
PMID: 32193290
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for -mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to...
7.
Ayeni D, Miller B, Kuhlmann A, Ho P, Robles-Oteiza C, Gaefele M, et al.
J Immunother Cancer
. 2019 Jul;
7(1):172.
PMID: 31291990
Background: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches to combine...
8.
Pirazzoli V, Ayeni D, Meador C, Sanganahalli B, Hyder F, de Stanchina E, et al.
Clin Cancer Res
. 2015 Sep;
22(2):426-35.
PMID: 26341921
Purpose: The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and afatinib, have transformed the treatment of advanced EGFR-mutant lung adenocarcinoma. However, almost all patients who respond develop acquired resistance on average...
9.
Ayeni D, Politi K, Goldberg S
Clin Cancer Res
. 2015 Jul;
21(17):3818-20.
PMID: 26169963
Third-generation mutant-specific EGFR tyrosine kinase inhibitors are showing robust clinical activity, particularly in lung cancers harboring the EGFR(T790M) mutation, yet acquired resistance to these agents emerges. Additional mutations in EGFR...
10.
Politi K, Ayeni D, Lynch T
Cancer Cell
. 2015 Jun;
27(6):751-3.
PMID: 26058074
The T790M mutation in EGFR accounts for approximately half of all lung cancer cases with acquired resistance to the current clinical EGFR tyrosine kinase inhibitors. In tyrosine kinase inhibitor-resistant lung...